Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trial

Peritoneal surface malignancies (PSMs) remain a therapeutic challenge, particularly in patients with unresectable disease who cannot benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TE...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	John H. Stewart, IV, Donna Niedzwiecki, Melissa Lowe, Ashley Moyer, Emily Bolch, Shannon Diane MacLaughlan, Edward A. Levine, Omeed Moaven, Niharika Mettu, John H. Strickler, Dan G. Blazer, III
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Elsevier 2026-03-01
Seri Bilgileri:	Molecular Therapy: Oncology
Konular:	MT: Regular Issue peritoneal surface malignancies talimogene laherparepvec T-VEC oncolytic virotherapy intraperitoneal therapy dose-escalation trial
Online Erişim:	http://www.sciencedirect.com/science/article/pii/S2950329925001808
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trial

Benzer Materyaller